Short Term Rating on Geron Corporation (GERN)

Geron Corporation (GERN) has an average broker rating of 1.5, which is interpreted as a Strong Buy, as rated by 4 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Geron Corporation (GERN) : The most positive equity analysts on Geron Corporation (GERN) expects the shares to touch $10, whereas, the least positive believes that the stock will trade at $6 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $7.5 with an expected fluctuation of $2.18 from the mean.

For the current week, the company shares have a recommendation consensus of Buy.


Geron Corporation (NASDAQ:GERN): The stock opened at $2.77 on Tuesday but the bulls could not build on the opening and the stock topped out at $2.78 for the day. The stock traded down to $2.69 during the day, due to lack of any buying support eventually closed down at $2.70 with a loss of -1.82% for the day. The stock had closed at $2.75 on the previous day. The total traded volume was 1,466,348 shares.

Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.